Skip to main content

Table 2 Patient dosimetry (N = 192)

From: Early toxicity and patient reported quality-of-life in patients receiving proton therapy for localized prostate cancer: a single institutional review of prospectively recorded outcomes

Variable No. (%) or
Median (Range)
Dose
  < 79.2 Gy (RBE) 27 (14.1%)
  ≥ 79.2 Gy (RBE) 165 (85.9%)
DVH Parameters
 Rectal wall V50, % 30.7 (8.0–56.6)
 Rectal wall V75, % 16.2 (0.0–30.6)
 Rectum V50, % 18.6 (2.0–39.4)
 Rectum V70, % 9.2 (0.0–34.7)
 Bladder wall V47, % 19.0 (6.8–56.7)
 Bladder wall V75, % 11.5 (0.0–37.0)
 Bladder V50, % 11.8 (2.1–58.5)
 Bladder V75, % 5.1 (0.0–35.5)
Femoral head mean dose
 Right, Gy 25.8 (15.4–41.1)
 Left, Gy 25.1 (11.3–39.9)
Femoral head max dose
 Right, Gy 35.6 (27.5–60.4)
 Left, Gy 35.6 (27.8–63.6)
 Penile bulb mean dose, Gy 45.1 (1.8–71.3)
 Bowel Max Dose, Gy (RBE)a 51.4 (46.0–54.0)
  1. aBased on patients receiving whole pelvis treatment